Literature DB >> 31451444

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.

Adam D Cohen1, Alfred L Garfall1, Ahmet Dogan2, Simon F Lacey1, Chris Martin3, Nikoletta Lendvai2, Dan T Vogl1, Matthew Spear3, Alexander M Lesokhin2,4.   

Abstract

Entities:  

Year:  2019        PMID： 31451444      PMCID： PMC6712532          DOI： 10.1182/bloodadvances.2019000466

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  11 in total

1.  Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

Authors:  Anja Seckinger; Jose Antonio Delgado; Samuel Moser; Laura Moreno; Brigitte Neuber; Anna Grab; Susanne Lipp; Juana Merino; Felipe Prosper; Martina Emde; Camille Delon; Melanie Latzko; Reto Gianotti; Remo Lüoend; Ramona Murr; Ralf J Hosse; Lydia Jasmin Harnisch; Marina Bacac; Tanja Fauti; Christian Klein; Aintzane Zabaleta; Jens Hillengass; Elisabetta Ada Cavalcanti-Adam; Anthony D Ho; Michael Hundemer; Jesus F San Miguel; Klaus Strein; Pablo Umaña; Dirk Hose; Bruno Paiva; Minh Diem Vu
Journal:  Cancer Cell       Date:  2017-03-02       Impact factor: 31.743

2.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

3.  B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Authors:  Adam D Cohen; Alfred L Garfall; Edward A Stadtmauer; J Joseph Melenhorst; Simon F Lacey; Eric Lancaster; Dan T Vogl; Brendan M Weiss; Karen Dengel; Annemarie Nelson; Gabriela Plesa; Fang Chen; Megan M Davis; Wei-Ting Hwang; Regina M Young; Jennifer L Brogdon; Randi Isaacs; Iulian Pruteanu-Malinici; Don L Siegel; Bruce L Levine; Carl H June; Michael C Milone
Journal:  J Clin Invest       Date:  2019-03-21       Impact factor: 14.808

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

5.  T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Authors:  Jennifer N Brudno; Irina Maric; Steven D Hartman; Jeremy J Rose; Michael Wang; Norris Lam; Maryalice Stetler-Stevenson; Dalia Salem; Constance Yuan; Steven Pavletic; Jennifer A Kanakry; Syed Abbas Ali; Lekha Mikkilineni; Steven A Feldman; David F Stroncek; Brenna G Hansen; Judith Lawrence; Rashmika Patel; Frances Hakim; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

6.  Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.

Authors:  Dalia A Salem; Irina Maric; Constance M Yuan; David J Liewehr; David J Venzon; James Kochenderfer; Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2018-07-18       Impact factor: 3.156

7.  Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

Authors:  Suzanne Trudel; Nikoletta Lendvai; Rakesh Popat; Peter M Voorhees; Brandi Reeves; Edward N Libby; Paul G Richardson; Larry D Anderson; Heather J Sutherland; Kwee Yong; Axel Hoos; Michele M Gorczyca; Soumi Lahiri; Zangdong He; Daren J Austin; Joanna B Opalinska; Adam D Cohen
Journal:  Lancet Oncol       Date:  2018-11-12       Impact factor: 41.316

8.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

9.  Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.

Authors:  Lydia Lee; Danton Bounds; Jennifer Paterson; Gaelle Herledan; Katherine Sully; Laura M Seestaller-Wehr; William E Fieles; James Tunstead; Lee McCahon; Fiona M Germaschewski; Patrick A Mayes; Jenny L Craigen; Manuel Rodriguez-Justo; Kwee L Yong
Journal:  Br J Haematol       Date:  2016-06-17       Impact factor: 6.998

10.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440
View more
  6 in total

Review 1.  Myeloma: next generation immunotherapy.

Authors:  Adam D Cohen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.

Authors:  Renier J Brentjens; Eric L Smith; Carlos Fernández de Larrea; Mette Staehr; Andrea V Lopez; Khong Y Ng; Yunxin Chen; William D Godfrey; Terence J Purdon; Vladimir Ponomarev; Hans-Guido Wendel
Journal:  Blood Cancer Discov       Date:  2020-09

3.  Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.

Authors:  Niels W C J van de Donk; Maria Themeli; Saad Z Usmani
Journal:  Blood Cancer Discov       Date:  2021-07

4.  Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Authors:  Liang Lin; Shih-Feng Cho; Lijie Xing; Kenneth Wen; Yuyin Li; Tengteng Yu; Phillip A Hsieh; Hailin Chen; Metin Kurtoglu; Yi Zhang; C Andrew Stewart; Nikhil Munshi; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Leukemia       Date:  2020-07-06       Impact factor: 11.528

5.  Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.

Authors:  Ricardo D Parrondo; Keren Sam; Ahsan Rasheed; Victoria Alegria; Taimur Sher; Vivek Roy; Asher Chanan-Khan; Sikander Ailawadhi
Journal:  Blood Cancer J       Date:  2022-04-19       Impact factor: 9.812

6.  "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Authors:  I Vaxman; J Abeykoon; A Dispenzieri; S K Kumar; F Buadi; M Q Lacy; D Dingli; Y Hwa; A Fonder; M Hobbs; C Reeder; T Sher; S Hayman; T Kourelis; R Warsame; E Muchtar; N Leung; R Go; W Gonsalves; M Siddiqui; R A Kyle; S V Rajkumar; McCullough Kristen; P Kapoor; M A Gertz
Journal:  Blood Cancer J       Date:  2021-12-07       Impact factor: 9.812
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.